UBA1 and myelodysplastic syndrome: According to Khitri et al., the VEXAS-RP group had a worse prognosis, greater death rate, older patients, a lower rate response to medication, and a higher frequency of skin lesions (82%), fever (58%), lung infiltrates (29%), and myelodysplastic syndrome (75%) [44]. The accuracy of VEXAS diagnosis needs genetic testing for UBA1 mutation, the same authors excluded from the genetic evaluation the patients older than 65 years old, with platelets count <200 k/μL and mean corpuscular volume >100 fL, which are more suitable for the primary RP.